Literature DB >> 21536933

Stereotactic body radiation therapy: scope of the literature.

Kelley Tipton1, Jason H Launders, Rohit Inamdar, Curtis Miyamoto, Karen Schoelles.   

Abstract

Stereotactic body radiation therapy (SBRT) is derived from the techniques of stereotactic radiosurgery used to treat lesions in the brain and spine. It combines multiple finely collimated radiation beams and stereotaxy to deliver a high dose of radiation to an extracranial target in the body in a single dose or a few fractions. This review provides a broad overview of the current state of SBRT for solid malignant tumors. Reviewers identified a total of 124 relevant studies. To our knowledge, no published comparative studies address the relative effectiveness and safety of SBRT versus other forms of external-beam radiation therapy. Stereotactic body radiation therapy seems to be widely diffused as a treatment of various types of cancer, although most studies have focused only on its use for treating thoracic tumors. Comparative studies are needed to provide evidence that the theoretical advantages of SBRT over other radiation therapies actually occur in the clinical setting; this area is currently being studied in only 1 small trial.

Entities:  

Mesh:

Year:  2011        PMID: 21536933     DOI: 10.7326/0003-4819-154-11-201106070-00343

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Dentofacial parameters explaining variability in retroclination of the maxillary central incisors.

Authors:  Bernd G Lapatki; Andreas Klatt; Jürgen Schulte-Mönting; Irmtrud E Jonas
Journal:  J Orofac Orthop       Date:  2007-03       Impact factor: 1.938

Review 2.  Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Authors:  Ralph M Meyer; Richard T Hoppe
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

Review 3.  Radioprotection of normal tissue cells.

Authors:  Patrick Maier; Frederik Wenz; Carsten Herskind
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

4.  Patient-clinician communication among patients with stage I lung cancer.

Authors:  Shannon M Nugent; Sara E Golden; Charles R Thomas; Mark E Deffebach; Mithran S Sukumar; Paul H Schipper; Brandon H Tieu; Drew Moghanaki; Juan Wisnivesky; Christopher Slatore
Journal:  Support Care Cancer       Date:  2017-12-05       Impact factor: 3.603

5.  The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.

Authors:  Bruce L Jacobs; Jonathan G Yabes; Samia H Lopa; Dwight E Heron; Chung-Chou H Chang; Florian R Schroeck; Justin E Bekelman; Jeremy M Kahn; Joel B Nelson; Amber E Barnato
Journal:  Cancer       Date:  2017-03-16       Impact factor: 6.860

6.  Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.

Authors:  Joshua A Halpern; Art Sedrakyan; Wei-Chun Hsu; Jialin Mao; Timothy J Daskivich; Paul L Nguyen; Encouse B Golden; Josephine Kang; Jim C Hu
Journal:  Cancer       Date:  2016-05-25       Impact factor: 6.860

Review 7.  Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?

Authors:  Sergey V Kozin; Dan G Duda; Lance L Munn; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2012-05-09       Impact factor: 13.506

Review 8.  Cancer and radiation therapy: current advances and future directions.

Authors:  Rajamanickam Baskar; Kuo Ann Lee; Richard Yeo; Kheng-Wei Yeoh
Journal:  Int J Med Sci       Date:  2012-02-27       Impact factor: 3.738

9.  A Survey of Stereotactic Body Radiotherapy in Korea.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo
Journal:  Cancer Res Treat       Date:  2014-11-24       Impact factor: 4.679

10.  In vivo optical imaging of tumor and microvascular response to ionizing radiation.

Authors:  Azusa Maeda; Michael K K Leung; Leigh Conroy; Yonghong Chen; Jiachuan Bu; Patricia E Lindsay; Shani Mintzberg; Carl Virtanen; Julissa Tsao; Neil A Winegarden; Yanchun Wang; Lily Morikawa; I Alex Vitkin; David A Jaffray; Richard P Hill; Ralph S DaCosta
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.